Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention

被引：2

作者：

Mangiacapra, Fabio ^{[1
]}

Sticchi, Alessandro ^{[1
]}

Bressi, Edoardo ^{[1
]}

Mangiacapra, Roberto ^{[2
,3
]}

Viscusi, Michele Mattia ^{[1
]}

Colaiori, Iginio ^{[1
]}

Ricottini, Elisabetta ^{[1
]}

Cavallari, Ilaria ^{[1
]}

Spoto, Silvia ^{[4
]}

Ussia, Gian Paolo ^{[1
]}

Ferraro, Pietro Manuel ^{[2
,3
]}

Grigioni, Francesco ^{[1
]}

机构：

[1] Campus Biomed Univ, Dept Med, Unit Cardiovasc Sci, Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, UOC Nefrol, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Rome, Italy

[4] Campus Biomed Univ, Dept Med, Unit Diagnost & Therapeut Med, Rome, Italy

来源：

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH | 2021年 / 14卷 / 06期

关键词：

Chronic kidney disease; Platelet reactivity; Percutaneous coronary intervention; Coronary artery disease; PERIPROCEDURAL MYOCARDIAL-INFARCTION; PATIENTS RECEIVING CLOPIDOGREL; DRUG-ELUTING STENTS; RENAL-FUNCTION; END-POINTS; ASSOCIATION; INHIBITION; IMPLANTATION; MECHANISMS; EFFICACY;

D O I：

10.1007/s12265-021-10126-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the interaction between chronic kidney disease (CKD) and high platelet reactivity (HPR) in determining long-term clinical outcomes following elective PCI for stable coronary artery disease (CAD). A total of 500 patients treated with aspirin and clopidogrel were divided based on the presence of CKD (defined as glomerular filtration rate of < 60 ml/min/1.73 m(2)) and HPR (defined as a P2Y12 reaction unit value >= 240 at VerifyNow assay). Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both CKD and HPR showed the highest estimates of MACE (25.6%, p = 0.005), all-cause death (17.9%, p = 0.004), and cardiac death (7.7%, p = 0.004). The combination of CKD and HPR was an independent predictor of MACE (HR 3.12, 95% CI 1.46-6.68, p = 0.003). In conclusion, the combination of CKD and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.

引用

页码：1085 / 1092

页数：8

共 36 条

[1] Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy
Angiolillo, Dominick J.
Bernardo, Esther
Capodanno, Davide
Vivas, David
Sabate, Manel
Ferreiro, Jose Luis
Ueno, Masafumi
Jimenez-Quevedo, Pilar
Alfonso, Fernando
Bass, Theodore A.
Macaya, Carlos
Fernandez-Ortiz, Antonio
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (11) : 1139 - 1146
[2] Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease
Anselmi, Chiara Viviani
Briguori, Carlo
Roncarati, Roberta
Papa, Laura
Visconti, Gabriella
Focaccio, Amelia
De Micco, Francesca
Latronico, Michael V. G.
Pagnotta, Paolo
Condorelli, Gianluigi
[J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (11) : 1166 - 1175
[3] Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
Aradi, Daniel
Kirtane, Ajay
Bonello, Laurent
Gurbel, Paul A.
Tantry, Udaya S.
Huber, Kurt
Freynhofer, Matthias K.
ten Berg, Jurrien
Janssen, Paul
Angiolillo, Dominick J.
Siller-Matula, Jolanta M.
Marcucci, Rossella
Patti, Giuseppe
Mangiacapra, Fabio
Valgimigli, Marco
Morel, Olivier
Palmerini, Tullio
Price, Matthew J.
Cuisset, Thomas
Kastrati, Adnan
Stone, GreggW.
Sibbing, Dirk
[J]. EUROPEAN HEART JOURNAL, 2015, 36 (27) : 1762 - 1771
[4] Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry
Baber, Usman
Mehran, Roxana
Kirtane, Ajay J.
Gurbel, Paul A.
Christodoulidis, Georgios
Maehara, Akiko
Witzenbichler, Bernhard
Weisz, Giora
Rinaldi, Michael J.
Metzger, D. Christopher
Henry, Timothy D.
Cox, David A.
Duffy, Peter L.
Mazzaferri, Ernest L., Jr.
Xu, Ke
Parise, Helen
Brodie, Bruce R.
Stuckey, Thomas D.
Stone, Gregg W.
[J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (06)
[5] The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting
Breet, Nicoline J.
de Jong, Corine
Bos, Willem Jan
van Werkum, Jochem W.
Bouman, Heleen J.
Kelder, Johannes C.
Bergmeijer, Thomas O.
Zijlstra, Felix
Hackeng, Christian M.
ten Berg, Jurrien M.
[J]. THROMBOSIS AND HAEMOSTASIS, 2014, 112 (06) : 1174 - 1181
[6] Antithrombotic Therapy in Patients With Chronic Kidney Disease
Capodanno, Davide
Angiolillo, Dominick J.
[J]. CIRCULATION, 2012, 125 (21) : 2649 - 2661
[7] Clinical end points in coronary stent trials - A case for standardized definitions
Cutlip, Donald E.
Windecker, Stephan
Mehran, Roxana
Boam, Ashley
Cohen, David J.
van Es, Gerrit-Anne
Steg, P. Gabriel
Morel, Marie-angele
Mauri, Laura
Vranckx, Pascal
McFadden, Eugene
Lansky, Alexandra
Hamon, Martial
Krucoff, Mitchell W.
Serruys, Patrick W.
[J]. CIRCULATION, 2007, 115 (17) : 2344 - 2351
[8] Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, Ron T.
Correa-Rotter, Ricardo
Hemmelgarn, Brenda R.
Jafar, Tazeen H.
Heerspink, Hiddo J. Lambers
Mann, Johannes F.
Matsushita, Kunihiro
Wen, Chi Pang
[J]. LANCET, 2013, 382 (9889) : 339 - 352
[9] Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy
Gremmel, Thomas
Mueller, Markus
Steiner, Sabine
Seidinger, Daniela
Koppensteiner, Renate
Kopp, Christoph W.
Panzer, Simon
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (08) : 2116 - 2122
[10] Hicks KA, 2015, J AM COLL CARDIOL, V66, P403, DOI [10.1007/s12350-015-0209-1, 10.1016/j.jacc.2014.12.018]

← 1 2 3 4 →